Top Medicare prescribers rake in speaking fees from drugmakers
When the blood pressure drug Bystolic hit the market in 2008, it faced a crowded field of cheap generics. So its maker, Forest Laboratories, launched a promotional assault on the group in the best position to determine Bystolic's success: those in control of prescription pads. It flooded the offices of health professionals with drug reps, and it hired doctors to persuade their peers to choose Bystolic ? even though the drug hadn't proved more effective than competitors. The strategy worked. In the 2012 fiscal year, sales of Bystolic reached $348 million, almost double its total from two years earlier, the company reported.
- Why Is Healthcare Price Transparency So Hard?
- 5 Hot Healthcare Ideas from SXSW
- EHR Spending Continues, But Jury Still Out on ROI
- Care Coordination a Cost-Cutting Quality Driver
- Adverse Events from Insulin Prescribing 'An Epidemic'
- Hospital Groups Strike Back at Hospital Rating Systems
- The Trouble with Hospital Price Transparency
- Hospital CEO Turnover Hits Record High
- Payers Detail Strategies That Drive Consumer Satisfaction
- The Secret to Physician Engagement? It's Not Better Pay